EP3978005A4 - Zusammensetzung zur vorbeugung, linderung oder behandlung des metabolischen syndroms, begleitet von adipositas und/oder diabetes, mit, als wirkstoff, einem komplex (ib-komplex) aus amlabaumextrakt und extrakt von gekeimter gerste - Google Patents

Zusammensetzung zur vorbeugung, linderung oder behandlung des metabolischen syndroms, begleitet von adipositas und/oder diabetes, mit, als wirkstoff, einem komplex (ib-komplex) aus amlabaumextrakt und extrakt von gekeimter gerste Download PDF

Info

Publication number: EP3978005A4
Authority: EP; European Patent Office
Prior art keywords: complex; obesity; diabetes; relief; prevention
Prior art date: 2019-05-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP20815311.4A

Other languages

English (en)

French (fr)

Other versions

EP3978005A1 (de

EP3978005B1 (de

Inventor

Hae-Yeon Lee

Jong-Lae Kim

Tae-Gi Kim

Mi-Ryeong PARK

Jong-Wook Lee

Jin-Seong Yang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hlscience Co Ltd

Original Assignee

Hlscience Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-30

Filing date

2020-05-19

Publication date

2023-03-15

2020-05-19 Application filed by Hlscience Co Ltd filed Critical Hlscience Co Ltd

2022-04-06 Publication of EP3978005A1 publication Critical patent/EP3978005A1/de

2023-03-15 Publication of EP3978005A4 publication Critical patent/EP3978005A4/de

2024-05-15 Application granted granted Critical

2024-05-15 Publication of EP3978005B1 publication Critical patent/EP3978005B1/de

Status Active legal-status Critical Current

2040-05-19 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Botany (AREA)
Mycology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP20815311.4A 2019-05-30 2020-05-19 Zusammensetzung zur verwendung in der vorbeugung, linderung oder behandlung des metabolischen syndroms, begleitet von adipositas und/oder diabetes, mit, als wirkstoff, einem komplex (ib-komplex) aus amlabaumextrakt und extrakt von gekeimter gerste Active EP3978005B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20190064098		2019-05-30
PCT/KR2020/006545 WO2020242113A1 (ko)	2019-05-30	2020-05-19	인디안구스베리 추출물과 새싹보리 추출물의 복합물(ib복합물)을 유효성분으로 포함하는 비만 및/또는 당뇨를 동반하는 대사증후군의 예방, 개선 치료용 조성물

Publications (3)

Publication Number	Publication Date
EP3978005A1 EP3978005A1 (de)	2022-04-06
EP3978005A4 true EP3978005A4 (de)	2023-03-15
EP3978005B1 EP3978005B1 (de)	2024-05-15

Family

ID=73553266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20815311.4A Active EP3978005B1 (de)	2019-05-30	2020-05-19	Zusammensetzung zur verwendung in der vorbeugung, linderung oder behandlung des metabolischen syndroms, begleitet von adipositas und/oder diabetes, mit, als wirkstoff, einem komplex (ib-komplex) aus amlabaumextrakt und extrakt von gekeimter gerste

Country Status (7)

Country	Link
US (1)	US12403172B2 (de)
EP (1)	EP3978005B1 (de)
JP (1)	JP7303582B2 (de)
KR (1)	KR102378396B1 (de)
CN (1)	CN114007631B (de)
TW (1)	TWI733458B (de)
WO (1)	WO2020242113A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102751170B1 (ko)	2021-10-06	2025-01-09	주식회사 에이치엘사이언스	인디안구스베리 추출물 및 새싹보리 추출물의 복합물(ib복합물)을 유효성분으로 포함하는 항노화 피부 개선용 조성물
KR102705253B1 (ko)	2022-06-09	2024-09-11	주식회사 맨드림	식물 복합추출물을 유효성분으로 포함하는 두피 및 모발개선용 화장료 조성물
CN119909105A (zh) *	2025-04-02	2025-05-02	合生元（广州）健康产品有限公司	一种用于降脂降糖的营养组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20150130128A (ko) *	2014-05-13	2015-11-23	대한민국(농촌진흥청장)	새싹보리 추출물을 포함하는 비만 억제용 조성물
CN103736071B (zh) *	2014-01-23	2016-05-11	西藏金哈达药业有限公司	一种具有辅助降血糖功效的组合物及其应用、制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006008526A (ja)	2004-06-22	2006-01-12	Taiyo Kagaku Co Ltd	生活習慣病予防・改善組成物
JP2006056836A (ja)	2004-08-20	2006-03-02	Taiyo Kagaku Co Ltd	脂肪組織特異分泌蛋白産生増強組成物
JP2006104094A (ja)	2004-10-01	2006-04-20	Taiyo Kagaku Co Ltd	α−グルコシダーゼ阻害剤
JP2008050301A (ja)	2006-08-24	2008-03-06	Prima Meat Packers Ltd	膵リパーゼ阻害剤
JP2008247871A (ja)	2007-03-30	2008-10-16	Taiyo Kagaku Co Ltd	内臓脂肪蓄積抑制組成物
JP2010202634A (ja) *	2008-06-05	2010-09-16	Green Kanpo Seiyaku Kk	生薬含有組成物及びその利用
JP4493725B1 (ja)	2009-10-02	2010-06-30	株式会社ファイナルフューチャーインターナショナル	脂肪分解促進作用を有する組成物
JP6043923B2 (ja)	2010-12-08	2016-12-14	株式会社東洋新薬	食事摂取に伴う血中中性脂肪上昇抑制剤
KR20140127003A (ko) *	2013-04-24	2014-11-03	대한민국(농촌진흥청장)	새싹보리 지상부 추출물을 유효성분으로 포함하는 비만 또는 지질대사 질환의 예방, 치료 또는 개선용 조성물 및 추출물 제조방법
FR3027228B1 (fr)	2014-10-20	2016-12-09	Valbiotis	Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
JP2015127339A (ja)	2015-03-26	2015-07-09	株式会社東洋新薬	抗糖化用組成物
JP5910901B1 (ja)	2015-03-27	2016-04-27	株式会社東洋新薬	Ｇｌｐ−１分泌促進剤
CN105146655A (zh)	2015-09-07	2015-12-16	王保红	含有茶树花的饮品组合物及其制备方法和应用
JP2017105728A (ja)	2015-12-10	2017-06-15	株式会社東洋新薬	血糖値上昇抑制剤及び整腸剤
KR20180003073A (ko)	2016-06-30	2018-01-09	재단법인 전남생물산업진흥원	새싹보리 추출물을 포함하는 비만 치료 또는 예방용 조성물
CN106605822A (zh)	2016-12-19	2017-05-03	西安源森生物科技有限公司	一种有利于降血糖的组合物及其制备方法
KR101830048B1 (ko)	2017-09-08	2018-02-19	주식회사 프롬바이오	가자나무열매추출물 및 암라추출물을 포함하는 비만 또는 고지혈증 개선용 식품 조성물
KR20190064098A (ko)	2017-11-30	2019-06-10	에스케이하이닉스 주식회사	반도체 장치, 및 그의 리페어 동작방법

2020
- 2020-05-19 US US17/614,749 patent/US12403172B2/en active Active
- 2020-05-19 JP JP2021570428A patent/JP7303582B2/ja active Active
- 2020-05-19 EP EP20815311.4A patent/EP3978005B1/de active Active
- 2020-05-19 KR KR1020200059964A patent/KR102378396B1/ko active Active
- 2020-05-19 WO PCT/KR2020/006545 patent/WO2020242113A1/ko not_active Ceased
- 2020-05-19 CN CN202080043217.4A patent/CN114007631B/zh active Active
- 2020-05-21 TW TW109116980A patent/TWI733458B/zh active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103736071B (zh) *	2014-01-23	2016-05-11	西藏金哈达药业有限公司	一种具有辅助降血糖功效的组合物及其应用、制备方法
KR20150130128A (ko) *	2014-05-13	2015-11-23	대한민국(농촌진흥청장)	새싹보리 추출물을 포함하는 비만 억제용 조성물

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Abstracts of The 47th Annual Conference of Research Society for the Study of Diabetes in India", INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, SPRINGER (INDIA) PRIVATE LTD, INDIA, vol. 39, no. Suppl 1, 1 November 2019 (2019-11-01), pages 1 - 42, XP036925362, ISSN: 0973-3930, [retrieved on 20191101], DOI: 10.1007/S13410-019-00782-7 *
"Medoharayogah - 2", 1 January 2000, India, article ANONYMOUS: "Medoharayogah - 2", pages: 1 - 3, XP093019030 *
AHMED M ET AL: "PHYTOCHEMICAL SCREENING, TOTAL PHENOLIC AND FLAVONOIDS CONTENTS AND ANTIOXIDANT ACTIVITIES OF CITRULLUS COLOCYNTHIS L. AND CANNABIS SATIVA L.", APPLIED ECOLOGY AND ENVIRONMENTAL RESEARCH, vol. 17, no. 3, 8 October 2019 (2019-10-08), pages 1 - 19, XP055862116, ISSN: 1589-1623, Retrieved from the Internet <URL:https://www.epa.hu/02500/02583/00059/pdf/EPA02583_applied_ecology_2019_3_69616979.pdf> DOI: 10.15666/aeer/1703_69616979 *
ALTIOK E ET AL: "Isolation of polyphenols from the extracts of olive leaves (Olea europaea L.) by adsorption on silk fibroin", SEPARATION AND PURIFICATION TECHNOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 62, no. 2, 1 September 2008 (2008-09-01), pages 342 - 348, XP022758139, ISSN: 1383-5866, [retrieved on 20080202], DOI: 10.1016/J.SEPPUR.2008.01.022 *
BYADGI PARAMESWARAPPAS ET AL: "Clinical assessment of dietary interventions and lifestyle modifications in Madhumeha (type- 2 Diabetes Mellitus)", AYU (MUMBAI), vol. 35, no. 4, 1 January 2014 (2014-01-01), IN, pages 391, XP093019041, ISSN: 0974-8520, Retrieved from the Internet <URL:https://www.ayujournal.org/temp/Ayu354391-5416723_150247.pdf> DOI: 10.4103/0974-8520.158997 *
D'SOUZA JASON JEROME ET AL: "Anti-diabetic effects of the Indian indigenous fruit Emblica officinalis Gaertn: active constituents and modes of action", FOOD & FUNCTION, vol. 5, no. 4, 1 January 2014 (2014-01-01), GB, pages 635, XP093019347, ISSN: 2042-6496, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2014/fo/c3fo60366k> DOI: 10.1039/c3fo60366k *
FATIMA NOOR ET AL: "Ellagic acid inEmblica officinalisexerts anti-diabetic activity through the action on [beta]-cells of pancreas", EUROPEAN JOURNAL OF NUTRITION, STEINKOPFF VERLAG, DARMSTADT, DE, vol. 56, no. 2, 22 November 2015 (2015-11-22), pages 591 - 601, XP036182925, ISSN: 1436-6207, [retrieved on 20151122], DOI: 10.1007/S00394-015-1103-Y *
See also references of WO2020242113A1 *
YAWEN ZENG ET AL: "Preventive and Therapeutic Role of Functional Ingredients of Barley Grass for Chronic Diseases in Human Beings", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2018, 1 January 2018 (2018-01-01), US, pages 1 - 15, XP055703281, ISSN: 1942-0900, DOI: 10.1155/2018/3232080 *

Also Published As

Publication number	Publication date
CN114007631B (zh)	2023-05-30
TW202106178A (zh)	2021-02-16
KR20200138003A (ko)	2020-12-09
US20220226421A1 (en)	2022-07-21
CN114007631A (zh)	2022-02-01
WO2020242113A1 (ko)	2020-12-03
EP3978005A1 (de)	2022-04-06
JP7303582B2 (ja)	2023-07-05
EP3978005B1 (de)	2024-05-15
KR102378396B1 (ko)	2022-03-24
TWI733458B (zh)	2021-07-11
US12403172B2 (en)	2025-09-02
JP2022535353A (ja)	2022-08-08

Legal Events

Date	Code	Title	Description
2020-12-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-03-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-03-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-04-06	17P	Request for examination filed	Effective date: 20211206
2022-04-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-08-01	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2022-09-07	DAV	Request for validation of the european patent (deleted)
2022-09-07	DAX	Request for extension of the european patent (deleted)
2023-03-15	A4	Supplementary search report drawn up and despatched	Effective date: 20230214
2023-03-15	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 3/10 20060101ALI20230208BHEP Ipc: A61P 3/04 20060101ALI20230208BHEP Ipc: A61K 31/7048 20060101ALI20230208BHEP Ipc: A61K 31/37 20060101ALI20230208BHEP Ipc: A61K 36/8998 20060101ALI20230208BHEP Ipc: A61K 36/185 20060101AFI20230208BHEP
2023-11-29	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: HLSCIENCE CO., LTD
2023-12-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-12-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-01-03	INTG	Intention to grant announced	Effective date: 20231208
2024-04-03	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20240226
2024-04-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2024-04-12	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2024-04-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2024-05-15	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-05-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2024-06-05	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-06-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602020031039 Country of ref document: DE
2024-09-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2024-09-18	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20240515
2024-10-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240915
2024-10-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240816
2024-10-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240916
2024-10-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1686390 Country of ref document: AT Kind code of ref document: T Effective date: 20240515
2024-10-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2024-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240916 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240815 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240915 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240816 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240815
2024-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-01-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240519
2025-01-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-01-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-01-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-01-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240519 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240531
2025-02-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-02-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602020031039 Country of ref document: DE
2025-02-21	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20240531
2025-03-21	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2025-03-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2025-04-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240519
2025-04-23	26N	No opposition filed	Effective date: 20250218
2025-04-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240531 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250325 Year of fee payment: 6
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250522 Year of fee payment: 6
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250526 Year of fee payment: 6
2025-09-02	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20200519
2025-09-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20200519
2025-09-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240515

Publication	Publication Date	Title
EP3978005A4 (de)	2023-03-15	Zusammensetzung zur vorbeugung, linderung oder behandlung des metabolischen syndroms, begleitet von adipositas und/oder diabetes, mit, als wirkstoff, einem komplex (ib-komplex) aus amlabaumextrakt und extrakt von gekeimter gerste
MA41562A1 (fr)	2018-05-31	Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA41135B1 (fr)	2021-10-29	Benzamides substitués 1,3-thiazol-2-yl
MA40523A (fr)	2017-06-14	2-(morpholin-4-yl)-1,7-naphthyridines
MA32171B1 (fr)	2011-03-01	Compose heterocyclique
EA200870216A1 (ru)	2009-02-27	Амидо соединения и их применение в качестве лекарственных средств
MA38398B1 (fr)	2018-09-28	Composés biaryle amides en tant qu'inhibiteurs de kinase
MA45020A (fr)	2019-03-27	Dérivés sulfonamides aromatiques
MA35422B1 (fr)	2014-09-01	Imidazopyridazines amino-substituees
MA33836B1 (fr)	2012-12-03	Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA54386B1 (fr)	2023-08-31	Modulateurs de trex1
MA38810A1 (fr)	2017-10-31	Inhibiteurs de rorc2 méthodes d'utilisation associées
EP2878305A4 (de)	2015-11-25	Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von stat3-vermittelten erkrankungen mit einem salvia plebeia-r. br.- extrakt oder einem teil davon als wirkstoff
EP3417853A4 (de)	2019-10-30	Pharmazeutische zusammensetzung zur behandlung von krebs mit einer polyphenolverbindung als wirkstoff
MA49560B1 (fr)	2024-05-31	Composés cétoniques bicycliques et leurs procédés d'utilisation
BR112012021657A2 (pt)	2016-09-27	composto, agentes farmacêutico, agonístico de casr, e agente para conferir kokumi, e, temperos
EP3868385A4 (de)	2021-12-22	Magenkrebsbehandlungszusammensetzung mit syt11-inhibitor als wirkstoff
MA53617A (fr)	2021-07-21	Composition pour inhiber l'activité de la trypsine, contenant, en tant que principe actif, une bactérie appartenant au genre paraprevotella
EP4015042A4 (de)	2023-06-07	Pharmazeutische zusammensetzung mit antimykotikum als wirkstoff
EP3698801A4 (de)	2021-07-21	Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes, mit zinksalz, cyclo-hispro und antidiabetischem arzneimittel als wirkstoffe
EP3821901A4 (de)	2021-08-11	Zusammensetzung zur verhinderung, linderung oder behandlung allergischer hauterkrankungen mit extrakt aus gardeniafrüchten als wirkstoff, aus denen pigmente entfernt werden
BR112021025288A2 (pt)	2022-03-08	Composição fungicida sinergística
EP3861866A4 (de)	2022-07-06	Zusammensetzung mit molokhia-extrakt als wirkstoff zur verbesserung des darmmikrobioms oder zur linderung, vorbeugung oder behandlung von intestinaler entzündung, leaky-gut-syndrom, fettleibigkeit oder metabolischer krankheit
EP3904518A4 (de)	2023-10-11	Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs mit tut4/7-expressionsmodulator
EP3603647A4 (de)	2021-01-06	Pharmazeutische zusammensetzung mit adenosinderivat zur prävention und behandlung von glaukom